A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific
antibody，and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the
CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation
antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T
cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection
is planned for the treatment of patients with multiple myeloma.